TABLE 4.
Summary of adverse eventsa
| AE | No. (%) of subjects |
||||
|---|---|---|---|---|---|
| Treatment A (n = 36) | Treatment B (n = 18) | Treatment C (n = 18) | Treatment D (n = 36) | Any BMS-663068 treatment (n = 36) | |
| All events | 4 (11.1) | 5 (27.8) | 7 (38.9) | 19 (52.8) | 21 (58.3) |
| Scleral icterus | 0 | 1 (5.6) | 2 (11.1) | 10 (27.8) | 11 (30.6) |
| Abdominal pain | 0 | 1 (5.6) | 3 (16.7) | 4 (11.1) | 5 (13.9) |
| Headache | 2 (5.6) | 0 | 2 (11.1) | 5 (13.9) | 7 (19.4) |
| Dizziness | 0 | 0 | 2 (11.1) | 2 (5.6) | 2 (5.6) |
| Nausea | 0 | 1 (5.6) | 1 (5.6) | 3 (8.3) | 4 (11.1) |
| Musculoskeletal chest pain | 0 | 0 | 2 (11.1) | 1 (2.8) | 1 (2.8) |
a
Adverse events reported in >10% subjects in at least one treatment. Treatment A, BMS-663068 at 600 mg BID; treatment B, BMS-663068 at 600 mg BID plus RTV at 100 mg QD; treatment C, ATV at 300 mg QD plus RTV at 100 mg QD; treatment D, BMS-663068 at 600 mg BID plus ATV at 300 mg QD plus RTV at 100 mg QD.